Marcia Brose, MD, PhD, discusses the treatment options for patients with thyroid cancer and NTRK fusions.
Marcia Brose, MD, PhD, director of the Center for Rare Cancers and Personalized Therapy, director of the Thyroid Cancer Therapeutics Program, associate professor of Otorhinolaryngology: Head and Neck Surgery at the Hospital of the University of Pennsylvania, and associate professor of Medicine at Penn Medicine, discusses the treatment options for patients with thyroid cancer and NTRK fusions.
There are 2 FDA-approved drugs for these patients, larotrectinib (Vitrakvi) and entrectinib (Rozlytrek). Both of these therapies target TRK fusions in patients with thyroid cancer. Brose says that the fusion happens because a TRK gene fuses with another gene. When that occurs, it activates a pathway which may have caused the patient’s cancer in the first place. Physicians test for these fusions to see if they can target the abnormal pathway with one of these agents, which gives them a chance to focus on the cause of the cancer.
Larotrectinib and entrectinib inhibit this gene, and as a result stop the cancer from growing, according to Brose. For many patients, these treatments cause a significant amount of shrinkage of their cancer; in some cases, it causes so much shrinkage that the patient’s disease cannot be found. Brose says we cannot think these patients are cured because there is no data to show that, but getting the disease burden down to be small enough that it can’t be found on a CAT scan is a new level of response that hasn’t been achieved with other agents.
<< View more resources and information regarding thyroid cancer
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
Anticipating Novel Options for the RAI-Refractory DTC Armamentarium
May 15th 2023In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.
Listen
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More